-

Silverback Therapeutics to Present at Upcoming Investor Conferences

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that Laura Shawver, Ph.D., Silverback’s chief executive officer, will present at the following upcoming investor conferences:

  • Event: Goldman Sachs West Coast Biotech Bus Tour
    Location: Virtual
    Date: Tuesday, February 23, 2021
    Time: 2:00 PM ET / 11:00 AM PT

  • Event: SVB Leerink 10th Annual Global Healthcare Conference
    Location: Virtual
    Date: Wednesday, February 24, 2021
    Time: 4:20 PM ET / 1:20 PM PT

  • Event: Cowen 41st Annual Healthcare Conference
    Location: Virtual
    Date: Wednesday, March 3, 2021
    Time: 3:20 PM ET / 12:20 PM PT

  • Event: H.C. Wainwright Global Life Sciences Conference
    Location: Virtual
    Date: Tuesday, March 9, 2021
    Time: 7:00 AM ET / 4:00 AM PT

The webcast and archived replay of the SVB Leerink, Cowen, and H.C. Wainwright presentations will be available on the Silverback website, www.silverbacktx.com, for 30 days.

About Silverback Therapeutics

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Silverback’s platform enables the strategic pairing of proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites. Initially, Silverback is creating a new class of targeted immuno-oncology agents that direct a TLR8 agonist myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing. Silverback Therapeutics is located in Seattle, Washington. To learn more, visit www.silverbacktx.com.

Contacts

Investor Contact:
Miguel Arcinas
Silverback Therapeutics
(206) 736-7946
ir@silverbacktx.com

Media Contact:
Steve E. Kunszabo
Canale Communications
(619) 849-5392
steve.kunszabo@canalecomm.com

Industry:

Silverback Therapeutics, Inc.

NASDAQ:SBTX
Release Versions
English

Contacts

Investor Contact:
Miguel Arcinas
Silverback Therapeutics
(206) 736-7946
ir@silverbacktx.com

Media Contact:
Steve E. Kunszabo
Canale Communications
(619) 849-5392
steve.kunszabo@canalecomm.com

More News From Silverback Therapeutics, Inc.

Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review ARS Pharmaceuticals, Inc.’s (ARS Pharma) New Drug Application (NDA) for neffy for the emergency treatment of allergic reactions (type I) including anaphylaxis in adults and children ≥30 kg (66 lbs). If approved by the FDA, neffy would be the first non-injectable treatment available to patients with allergic reactions (type...

Silverback Therapeutics and ARS Pharmaceuticals Announce Merger

SEATTLE & SAN DIEGO--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”) and ARS Pharmaceuticals, Inc. (“ARS”) today announced that the companies have entered into a definitive agreement under which ARS will merge with Silverback in an all-stock transaction. The combined company will focus on the potential regulatory approval and commercialization of neffy, ARS’s investigational epinephrine nasal spray for the treatment of Type I allergic reactions including anaphylaxis...

Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today announced that Silverback management will participate in the H.C. Wainwright 24th Global Investment Conference from May 23-25, 2022. Laura Shawver, Ph.D., Silverback’s Chief...
Back to Newsroom